Stock AnalizPtc Therapeutics, Inc. PTCT
Biotechnology: Pharmaceutical Preparations · IPO 2013 · data as of November 13, 2026
Ptc Therapeutics, Inc. (PTCT) is a healthcare company listed in the US with a market value of about $5.3B. In the twelve months to September 30, 2026 it had revenue of $1.2B and net income of -$106M, a net margin of -9.2%.
Its overall Stock Analiz score is 1.8 out of 5 (weak). The strongest part is future growth (4/5); the weakest is value (0/5).
Key numbers: a price to free cash flow of 2566.0, 5-year revenue growth of 35% a year, a 5-year average ROIC of 90%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 95% below the current price.
Score: 1.8 / 5
Checks passed
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- Profit margin improving
- Strong R&D investment or growth above 20%
- 5-year revenue growth above 8% a year
- 5-year average ROIC above 12%
- More cash than debt, or low debt to equity
- Positive free cash flow
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- 3-year free cash flow growth above 10% a year
- 5-year EPS growth above 10% a year
- Profitable 5 years in a row
Valuation
Growth and quality
Financials, last 10 years
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1.2B | $1.7B | $807M | $938M | $699M | $539M | $381M | $307M | $265M | $194M | $83M |
| Net income | -$106M | $683M | -$363M | -$627M | -$559M | -$524M | -$438M | -$252M | -$128M | -$79M | -$142M |
| Free cash flow | $2M | $702M | -$114M | -$187M | -$389M | -$280M | -$212M | -$112M | -$35M | -$13M | -$105M |
| EPS (diluted) | $-1.40 | $7.78 | $-4.73 | $-8.37 | $-7.79 | $-7.43 | $-6.64 | $-4.27 | $-2.75 | $-2.02 | $-4.17 |
| Net margin | -9.2% | 39.4% | -45.0% | -66.8% | -80.0% | -97.3% | -115.1% | -82.0% | -48.4% | -40.6% | -171.8% |
| ROIC | — | 453.4% | — | — | -127.1% | -57.6% | -38.9% | -20.7% | -22.5% | -16.9% | -47.9% |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
What analysts expect
The average 12-month price target from 15 analysts is $100.47, 58% above the current price; targets range from $62.00 to $137.00; the consensus rating is “Buy”; expected EPS is $0.94 for the fiscal year ending December 31, 2026.
Frequently asked questions
Is Ptc Therapeutics stock undervalued?
Our DCF model with moderate assumptions puts its intrinsic value about 95% below the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.
Does Ptc Therapeutics pay a dividend?
Not currently.
Is Ptc Therapeutics a good stock to buy?
We do not give buy or sell advice. Ptc Therapeutics scores 1.8 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.